- Conditions
- Pancreatic Cancer (Unresectable)
- Interventions
- FG-3019, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 296
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Recurrent Pancreatic Cancer, Somatostatinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- Capecitabine, Temozolomide, Bevacizumab
- Drug · Biological
- Lead sponsor
- Shaheen Shagufta
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Well-differentiated Pancreatic Neuroendocrine Tumor
- Interventions
- sunitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 2
- States / cities
- Orange, California • New York, New York
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
- Interventions
- erlotinib hydrochloride, gemcitabine hydrochloride, Oxaliplatin, radiation therapy
- Drug · Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Pancreatic Cancer
- Interventions
- Suizenji (an ultrasound-guided HIFU therapy system), Nal-IRI/FL, mFOLFIRINOX adjuvant chemotherapy, Gem/nab-PTX
- Device · Drug
- Lead sponsor
- SONIRE Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cancer
- Interventions
- aminocamptothecin colloidal dispersion
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma, Metastatic Pancreatic Neuroendocrine Carcinoma, Refractory Digestive System Neuroendocrine Carcinoma, Refractory Pancreatic Neuroendocrine Carcinoma, Unresectable Digestive System Neuroendocrine Carcinoma, Unresectable Pancreatic Neuroendocrine Carcinoma
- Interventions
- Fluorouracil, Leucovorin, Liposomal Irinotecan, Quality-of-Life Assessment
- Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Stony Brook, New York
- Conditions
- Pancreatic Cancer Non-resectable
- Interventions
- NanoKnife
- Device
- Lead sponsor
- Englewood Hospital and Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Englewood, New Jersey
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
- Interventions
- Futibatinib, Pembrolizumab, Cisplatin, 5-FU, Oxaliplatin, Leucovorin, Levoleucovorin, Irinotecan
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 16
- States / cities
- Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
- Interventions
- porfimer sodium
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Unresectable Pancreatic Carcinoma
- Interventions
- AZD1775, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Cleveland, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- Cancer
- Interventions
- isolated perfusion, melphalan
- Drug
- Lead sponsor
- Delcath Systems Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Histologically or Cytologically Confirmed Pancreatic Cancer, Unresectable or Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Cancer, Metastatic Pancreatic Cancer
- Interventions
- M7824, M9241, SBRT
- Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Refractory Colorectal Carcinoma, Refractory Lung Small Cell Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Carcinoma
- Interventions
- Berzosertib, Biopsy Specimen, Biospecimen Collection, Computed Tomography, Irinotecan Hydrochloride
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more
- Conditions
- Pancreatic Cancer
- Interventions
- TH-302, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- ImmunoGenesis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • St Louis, Missouri + 1 more
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
- Interventions
- Investigational informed consent for chemotherapy, Usual, standard-of-care informed consent for chemotherapy
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- San Francisco, California • Boston, Massachusetts • Milford, Massachusetts + 4 more
- Conditions
- Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
- Interventions
- BET Bromodomain Inhibitor ZEN-3694, Computed Tomography, Core Biopsy, Entinostat
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Gainesville, Florida • Oklahoma City, Oklahoma
- Conditions
- Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, irinotecan hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 7
- States / cities
- Chapel Hill, North Carolina • Goldsboro, North Carolina • Greenville, North Carolina + 4 more
- Conditions
- Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer, Thromboembolism
- Interventions
- dalteparin, gemcitabine hydrochloride, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- Gary Morrow
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 13
- States / cities
- Mobile, Alabama • Denver, Colorado • Chicago, Illinois + 10 more
- Conditions
- Pancreatic Cancer
- Interventions
- INTENSITY MODULATED RADIOTHERAPY, Gemcitabine
- Radiation · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan
- Conditions
- Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer, Advanced Pancreatic Adenocarcinoma
- Interventions
- Lm-LLO-TT
- Biological
- Lead sponsor
- Loki Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Pancreatic Cancer, Unresectable Biliary-pancreatic Malignancies
- Interventions
- ERCP with SEMS plus radiofrequency ablation, ERCP with SEMS alone (standard of care)
- Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
- Interventions
- BI 765049
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 1 more